Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli ...

Investor excitement about news of a fresh product launch ... Zepbound. It's also gearing up to sell biosimilars of Novo Nordisk diabetes treatment liraglutide. Investors plowed into Hims & Hers ...

Hims & Hers stirred the weight-loss waters by announcing it now offers prescriptions for Zepbound, Eli Lilly’s premium GLP-1 ...

Hims & Hers is a newfangled telehealth company that ... Then, on 5/20/24, HIMS metaphorically pushed harder on the launch button. It announced it would make GLP-1 injections available to its ...

Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued ... Companies like Hims & Hers and WeightWatchers have been providing compounded ...